Skip to main content

Peer Review reports

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

Original Submission
13 May 2021 Submitted Original manuscript
1 Jun 2021 Author responded Author comments - Tomoyuki Matsunaga
Resubmission - Version 2
1 Jun 2021 Submitted Manuscript version 2
21 Sep 2021 Reviewed Reviewer Report
29 Sep 2021 Reviewed Reviewer Report
29 Oct 2021 Author responded Author comments - Tomoyuki Matsunaga
Resubmission - Version 3
29 Oct 2021 Submitted Manuscript version 3
1 Mar 2022 Reviewed Reviewer Report
2 Mar 2022 Reviewed Reviewer Report
8 Mar 2022 Reviewed Reviewer Report
30 Mar 2022 Author responded Author comments - Tomoyuki Matsunaga
Resubmission - Version 4
30 Mar 2022 Submitted Manuscript version 4
Publishing
2 Apr 2022 Editorially accepted
15 Apr 2022 Article published 10.1186/s12885-022-09482-8

You can find further information about peer review here.

Back to article page